Nuzenio

Foghorn Therapeutics Inc

Foghorn Therapeutics Inc news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 11 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 11:46:00 GMT H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $13 - MoomooMoomoo · Fri, 07 Aug 2026 11:31:00 GMT Discipline and Rules-Based Execution in FHTX Response - Stock Traders DailyStock Traders Daily · Fri, 07 Aug 2026 03:36:02 GMT Foghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 14:20:38 GMT Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 13:50:06 GMT Foghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:11:00 GMT Lilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock TitanStock Titan · Thu, 06 Aug 2026 11:03:33 GMT Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 11:00:00 GMT

Timeline

Fri, 07 Aug 2026 11:46:00 GMTFoghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail

Fri, 07 Aug 2026 11:31:00 GMTH.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $13 - Moomoo

Fri, 07 Aug 2026 03:36:02 GMTDiscipline and Rules-Based Execution in FHTX Response - Stock Traders Daily

Thu, 06 Aug 2026 14:20:38 GMTFoghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView

Thu, 06 Aug 2026 13:50:06 GMTFoghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Thu, 06 Aug 2026 11:11:00 GMTFoghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingView

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

FHTX10 live mentions Reports3 live mentions Inc3 live mentions Foghorn Therapeutics3 live mentions Results2 live mentions Wainwright Maintains Foghorn2 live mentions Therapeutics2 live mentions With Buy Rating2 live mentions Maintains Target Price2 live mentions Discipline2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Foghorn Therapeutics Inc.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.